The stock of TransMedics Group Inc. (NASDAQ:TMDX) increased by $0.16 on Friday to finish at $62.51, up 0.26 percent. The last five days have seen an average of 598,600 shares of common stock traded. 25 times new highs were reached in the current year, with a gain of $0.79. The average number of shares traded over the last 20 days was 975,480, while the average volume over the last 50 days totaled 636,386.
TMDX stock dropped -30.17% since last month. On 08/15/23, the company’s shares reached a one-month low of $60.61. The stock touched a high of $99.63 on 07/19/23, after rallying from a low of $38.86 in 52 weeks. The price of TMDX stock has risen by 1.28% or $0.79 this year, reaching a new high 25 times. Still, the stock price is down -37.26% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
TMDX stock investors should be aware that TransMedics Group Inc. (TMDX) stock had its last reported insider trading activity 27 days ago on Aug 01. On Aug 01, President & CEO Hassanein Waleed H sold 7,500 shares at $93.06 each. This transaction resulted in the insider making $697,929. On Jul 18, Khayal Tamer I sold 5,000 shares at a price of US$95.37. After the transaction, the insider now owns 14,375 shares. Chief Commercial Officer Khayal Tamer I had earlier sold 2,974 shares on Jul 13 for $90.05 a share. The transaction was completed for $267,809.
Valuation Metrics
Beta for the stock is 1.57. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 13.47, the price-to-book (PB) ratio of 14.02.
Financial Health
For the recent quarter, TransMedics Group Inc.’s quick ratio was 19.70, while its current ratio was 20.70, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the recent quarter is 3.48, and the total debt to equity ratio is 3.48. As far as profitability goes, gross margin for the trailing twelve months is 69.10% percent. TransMedics Group Inc.’s EBITDA margin for the recent year was -29.15%, whereas its operating margin stood at -9.70% for the same period. Based on annual data, it had gross profit of $65.27 million and revenue of $93.46 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. TMDX’s return on assets (ROA) during the last 12 months has been -4.70%. There was a -12.60% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -10.00%.
Earnings Surprise
A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $52.47 million, while revenues rose by 60.89% to $41.55 million. EBITDA was $0.49 million for the quarter. At the end of TransMedics Group Inc.’s most recent quarter, its liabilities totaled 545.14 million, while its total debt was $515.01 million. Equity owned by shareholders amounts to $32.63 million.
Technical Picture
Here’s a quick look at TransMedics Group Inc.’s (TMDX) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 24.43%, suggesting the stock is oversold, with a 33.85% historical volatility rate.
The stochastic %K and %D were 18.03% and 17.54% respectively, while the average true range (ATR) was 3.26. Based on the 14-day stochastic reading of 22.99%, the RSI (14) reading is 27.33%. On the 9-day MACD Oscillator, the stock is at -0.56, and the 14-day reading is at -0.74.
Analyst Ratings
In its analyst report released on July 19, 2023, Robert W. Baird began covering TransMedics Group Inc. (NASDAQ: TMDX). The stock was rated as an Outperform by the brokerage firm. Analysts have assigned TransMedics Group Inc. (TMDX) an Buy rating. TMDX is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 5 others recommend it as a buy.
What is TMDX’s price target for the next 12 months?
The current consensus forecast for the stock is between $81.00 and $110.00, with a median target price of $99.00. In analyzing these forecasts, the average price target given by analysts for TransMedics Group Inc. (TMDX) is $96.20.
